BTIG raised the firm’s price target on Idexx Laboratories (IDXX) to $830 from $785 and keeps a Buy rating on the shares after its “strong” Q3 earnings beat. The growth was broad based and the quality of the beat was high, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating
- IDEXX Laboratories Reports Strong Q3 2025 Results
- Idexx Laboratories price target raised to $790 from $700 at BofA
- Idexx Laboratories price target raised to $785 from $745 at Leerink
- Idexx Laboratories price target raised to $775 from $700 at Stifel